IPDA for High-Priority HIV-1 Subtypes to Enable Global Eradication Trials

Accelevir Diagnostics, Llc, Baltimore MD

Investigators

Abstract

Sequence-based Assays to Quantify the Replication-Competent HIV Reservoir: Despite effective antiretroviral therapy (ART), HIV-1 persists in all infected individuals as proviral DNA within long-lived memory CD4+ T cells. This replication-competent HIV reservoir constitutes the primary barrier for curing HIV infection. The overall goal of this program is to develop and commercialize sequence-based HIV reservoir assays for clinical HIV cure interventions. Specifically, the assay should be designed as an analytical tool to monitor the size of the replication-competent HIV reservoir in clinical research and if successful, in prospective clinical trials.